美国食品和药物管理局曾授予seclidemstat快速通道指...查看全文
chuminhua2022-10-19 12:50
10月18日,Salarius Pharmaceuticals 周二表示,它已自愿暂停其口服 LSD1抑制剂 seclidemstat 的 I/II 期试验的招募,导致股价下跌多达 45%。此举是由该研究中一名患者的死亡引发的,该研究正在评估 seclidemstat 作为尤文肉瘤和其他 FET 重排肉瘤的潜在治疗方法。
根据 Salarius 的说法,死亡...查看全文
$Salarius Pharmaceuticals(SLRX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001615219-22-000151 Act: 34 Size: 317 KB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001615219-22-000150 Act: 34 Size: 3 MB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001615219-22-000147 Act: 34 Size: 363 KB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001615219-22-000143 Size: 5 KB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 4/A [Amend] Statement of changes in beneficial ownership of securities Accession Number: 0001615219-22-000144 Size: 6 KB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001615219-22-000142 Size: 6 KB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001615219-22-000141 Size: 4 KB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 8-K Current report, item 8.01 Accession Number: 0001615219-22-000140 Act: 34 Size: 240 KB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001615219-22-000139 Act: 34 Size: 5 MB 网页链接
$Salarius Pharmaceuticals(SLRX)$ 8-K Current report, item 8.01 Accession Number: 0001615219-22-000137 Act: 34 Size: 369 KB 网页链接